Literature DB >> 16944309

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.

Marc C Chamberlain1, Michael J Glantz, Lisa Chalmers, Alixis Van Horn, Andrew E Sloan.   

Abstract

Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16944309     DOI： 10.1007/s11060-006-9241-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  7 in total

Review 1.  Brain tumors.

Authors:  L M DeAngelis
Journal:  N Engl J Med       Date:  2001-01-11       Impact factor: 91.245

Review 2.  Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.

Authors:  M C Y de Wit; H G de Bruin; W Eijkenboom; P A E Sillevis Smitt; M J van den Bent
Journal:  Neurology       Date:  2004-08-10       Impact factor: 9.910

3.  Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.

Authors:  Roger Stupp; Pierre-Yves Dietrich; Sandrine Ostermann Kraljevic; Alessia Pica; Ivan Maillard; Phillipe Maeder; Reto Meuli; Robert Janzer; Gianpaolo Pizzolato; Raymond Miralbell; François Porchet; Luca Regli; Nicolas de Tribolet; René O Mirimanoff; Serge Leyvraz
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

Review 4.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.

Authors:  L A Stewart
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

5.  Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas.

Authors:  Michael Glantz; Marc Chamberlain; Qin Liu; N Scott Litofsky; Lawrence D Recht
Journal:  Cancer       Date:  2003-05-01       Impact factor: 6.860

6.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

7.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch
Journal:  J Natl Cancer Inst       Date:  1993-05-05       Impact factor: 13.506
  7 in total
  128 in total

1.  Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.

Authors:  Martin K Hunn; Evelyn Bauer; Catherine E Wood; Olivier Gasser; Marina Dzhelali; Lindsay R Ancelet; Brigitta Mester; Katrina J Sharples; Michael P Findlay; David A Hamilton; Ian F Hermans
Journal:  J Neurooncol       Date:  2014-10-31       Impact factor: 4.130

2.  Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Authors:  David A Reardon; Andrew D Norden; Annick Desjardins; James J Vredenburgh; James E Herndon; April Coan; John H Sampson; Sridharan Gururangan; Katherine B Peters; Roger E McLendon; Julie A Norfleet; Eric S Lipp; Jan Drappatz; Patrick Y Wen; Henry S Friedman
Journal:  J Neurooncol       Date:  2011-09-22       Impact factor: 4.130

3.  Development of a novel animal model to differentiate radiation necrosis from tumor recurrence.

Authors:  Sanath Kumar; Ali S Arbab; Rajan Jain; Jinkoo Kim; Ana C deCarvalho; Adarsh Shankar; Tom Mikkelsen; Stephen L Brown
Journal:  J Neurooncol       Date:  2012-03-10       Impact factor: 4.130

Review 4.  Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging.

Authors:  Rajan Jain; Jayant Narang; Pia M Sundgren; David Hearshen; Sona Saksena; Jack P Rock; Jorge Gutierrez; Tom Mikkelsen
Journal:  J Neurooncol       Date:  2010-02-24       Impact factor: 4.130

5.  Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.

Authors:  Ufuk Abacioglu; Hale B Caglar; Perran F Yumuk; Zuleyha Akgun; Beste M Atasoy; Meric Sengoz
Journal:  J Neurooncol       Date:  2010-09-29       Impact factor: 4.130

Review 6.  Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology.

Authors:  Alba A Brandes; Alicia Tosoni; Federica Spagnolli; Giampiero Frezza; Marco Leonardi; Fabio Calbucci; Enrico Franceschi
Journal:  Neuro Oncol       Date:  2008-04-09       Impact factor: 12.300

7.  Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

Authors:  Jerrold L Boxerman; Zheng Zhang; Yair Safriel; Mykol Larvie; Bradley S Snyder; Rajan Jain; T Linda Chi; A Gregory Sorensen; Mark R Gilbert; Daniel P Barboriak
Journal:  Neuro Oncol       Date:  2013-06-19       Impact factor: 12.300

8.  Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.

Authors:  Morad Nasseri; Seymur Gahramanov; Joao Prola Netto; Rongwei Fu; Leslie L Muldoon; Csanad Varallyay; Bronwyn E Hamilton; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2014-02-11       Impact factor: 12.300

9.  Oligodendroglioma confers higher risk of radiation necrosis.

Authors:  Haroon Ahmad; David Martin; Sohil H Patel; Joseph Donahue; Beatriz Lopes; Benjamin Purow; David Schiff; Camilo E Fadul
Journal:  J Neurooncol       Date:  2019-09-23       Impact factor: 4.130

10.  Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.

Authors:  David M Peereboom; Dale R Shepard; Manmeet S Ahluwalia; Cathy J Brewer; Neeraj Agarwal; Glen H J Stevens; John H Suh; Steven A Toms; Michael A Vogelbaum; Robert J Weil; Paul Elson; Gene H Barnett
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.